Canada: Passage Of Bill 21 Brings Significant Changes To Hospital Pharmacy And Health Professional Regulation

Bill 21, the Safeguarding Health Care Integrity Act, 2014  received Royal Assent on December 11, 2014 bringing about significant changes to the oversight of hospital pharmacies and regulated health professionals. The Bill amended a number of key statutes and also created the Voluntary Blood Donations Act, 2014.

Regulation of Hospital Pharmacies by the Ontario College of Pharmacists

Bill 21 amends the Drug and Pharmacies Regulation Act ("DPRA") to expand the oversight authority of the Ontario College of Pharmacists ("OCP") to include hospital and institutional pharmacies. While future regulations will designate premises "in or associated with one or more health custodial institutions" as an "institutional pharmacy," the recent amendments deem the following locations to be a "hospital pharmacy" for the purpose of the DPRA:

...where drugs are compounded, dispensed or supplied for hospital patients by a hospital in premises located in a hospital, the primary location or locations in the hospital where drugs are compounded, dispensed or supplied from, together with any other locations in the hospital where drugs are stored or supplied from and any other location prescribed in regulations...

In order to continue operating, a hospital pharmacy must be accredited by the OCP. The OCP will monitor compliance with DPRA provisions and any terms and conditions of licence through its authority to enter, search and examine (under warrant) areas deemed to be a hospital pharmacy.

It should be noted that only certain provisions of the DPRA apply to a hospital pharmacy and some provisions do not apply in the same way to hospital and other (community) pharmacies. The OCP also has authority to make regulations in respect of a hospital pharmacy, including with regard to inspections, operations and standards.

By giving the OCP authority to licence and inspect hospital and institutional pharmacies, the amendments have effectively implemented a key recommendation made by Dr. Thiessen in his report A Review of the Oncology Under-Dosing Incident, following his investigation into the March 2013 discovery of diluted chemotherapy drugs at a number of Ontario hospitals. We provided an overview of the report in a previous Health Communiqué.

Amendments to the DPRA will not come into force until supporting regulations regarding inspection criteria and operation and licensing standards of hospital and institutional pharmacies are developed.

Expanded Oversight of Regulated Health Professionals

Bill 21 also increases the oversight of regulated health professionals by introducing new mandatory reporting requirements to health regulatory colleges in the Public Hospitals Act and the Health Professions Procedural Code, Schedule 2 to the Regulated Health Professions Act ("RHPA"). Combined with amendments to the RHPA that expand exceptions to a health regulatory college's duty of confidentiality, these amendments are expected to support colleges in more efficiently identifying and effectively responding to issues regarding a member's professional practice. The expanded exception in the RHPA now permits health regulatory colleges to communicate otherwise confidential information to a hospital, as well as others prescribed by legislation, in the course of investigating a complaint about a member. These provisions are not yet in force.

Voluntary Blood Donation System in Ontario Maintained

The Voluntary Blood Donations Act, 2014 ("VBDA") preserves the public and voluntary blood donation system in Ontario and specifically prohibits payment (including reimbursement for expenditures of any kind) for blood and blood constituents (i.e. plasma) except in exceptional circumstances. The VBDA makes it an offence punishable by significant fines to pay or offer an individual payment for blood and for a donor to accept any payments. Canadian Blood Services ("CBS") and its donors are explicitly exempted from the payment prohibition. Where it is deemed necessary, CBS donors may be paid for blood donations. Blood donated "solely for the purpose of research" as defined in the VBDA is also excluded from the payment prohibitions.

Inspectors appointed under the VBDA have broad authority to enter, inspect and remove records or other items from a blood collection facility, any place perceived to be one, and any business that owns or operates such a facility. Compliance orders may be issued for not complying with the payment prohibitions.

Related amendments were made to other legislation, including the following:

  • The general entitlement under the Laboratory and Specimen Collection Centre Licensing Act to be issued a licence to establish, operate or maintain a laboratory or specimen collection centre subject to meeting statutory requirements, will not apply where the laboratory or specimen collection centre will operate as a blood collection facility within the meaning of the VBDA and the Minister is of view that issuing a licence is not in the public interest; and
  • The Trillium Gift of Life Network Act, which prohibits the sale or purchase of any tissue for a transplant of any body part or parts thereof for therapeutic purposes, medical education or scientific research, was amended to exclude "blood and blood constituents" from the definition of tissue. The impact of this amendment is that any payment prohibition for blood and blood constituents is exclusively governed by the VBDA.

The VBDA came into force on December 11, 2014, the day Bill 21 received Royal Assent.

Practical Implications

The passing of Bill 21, the Safeguarding Health Care Integrity Act, 2014 has broad implications for health industry clients. From a risk management perspective, hospitals and other entities that employ or offer privileges to a regulated health professional should establish clear protocols for meeting the new mandatory reporting requirements to health regulatory colleges, and for acting upon confidential information provided by college investigators.

Public and private hospitals and organizations likely to be deemed an institutional pharmacy will need to review their medication management processes to determine the legal and operational implications of these changes.  Given the broad definition of "hospital pharmacy", the legislation extends well beyond what might traditionally be thought of as a "pharmacy".  It extends to locations in the hospital where drugs are compounded, dispensed, stored or supplied, whether or not the activity is being carried out by pharmacists or other regulated health professionals such as registered nurses.  Even if a hospital does not operate a pharmacy or employ a pharmacist, the OCP may still consider whether the hospital has safe medication practices in place in relation to these premises.

Hospital Boards of Directors and senior leadership will need to consider the broader systemic implications of these changes, recognizing the obligation to ensure that appropriate systems are in place for safe medication management.  The legislation provides an excellent opportunity for hospitals to take an enterprise risk approach to identify, review and prioritize potential risks and to develop strategies to eliminate, manage or transfer risk, where possible. 

The OCP has circulated draft inspection criteria for hospital pharmacies which will be used for conducting baseline assessments of pharmacy practices and medication management.  They will be visiting all Ontario hospitals to conduct the baseline assessments.  In addition, the OCP is in the process of drafting the regulations to support Bill 21, which will be followed by a public consultation process.  It is anticipated that regulations will be in place by the end of the year.

We encourage hospitals to actively participate in the assessments, processes and consultations that are taking place to ensure there will be consideration of the unique environment in which hospital pharmacies operate.   

We will be following the process closely and invite you to contact us if you have questions about the Safeguarding Health Care Integrity Act, 2014, how it may impact your organization, and for assistance and advice with addressing the changes.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Kathryn Frelick
Sarah Virani (Student at Law)
Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions